Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Сен. 19, 2024

Abstract Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-controlled, multicenter phase 3 study (NCT05074589) assessed the efficacy and safety of liposomal HR070803 combined 5-fluorouracil (5-FU) leucovorin (LV) this patient population. Patients unresectable, locally advanced, PDAC had previously received therapies were randomized 1:1 to receive either (60 mg/m 2 anhydrous hydrochloride, equal 56.5 free base) placebo, both combination 5-FU (2000 ) LV (200 ), all given intravenously every two weeks. The primary endpoint was overall survival (OS). A total 298 enrolled plus 5-FU/LV (HR070803 group, n = 149) placebo (placebo 149). Median OS significantly improved group compared (7.4 months [95% CI 6.1–8.4] versus 5.0 4.3–6.0]; HR 0.63 0.48–0.84]; two-sided p 0.0019). most common grade ≥ adverse events increased gamma-glutamyltransferase (19.0% 11.6% group) decreased neutrophil count (12.9% 0 group). No treatment-related deaths occurred while reported one death (abdominal infection). manageable second-line setting, representing a potential option

Язык: Английский

---

Therapeutical potential of natural products in treatment of pancreatic cancer: a review

Molecular Biology Reports, Год журнала: 2025, Номер 52(1)

Опубликована: Янв. 31, 2025

Язык: Английский

---

Surgical Treatment of Pancreatic Ductal Adenocarcinoma

Cancers, Год журнала: 2021, Номер 13(8), С. 1971 - 1971

Опубликована: Апрель 20, 2021

Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival less than 10%. Although there are improvements for multimodal therapy PDAC, surgery remains effective way to treat disease. Combined adjuvant and/or neoadjuvant treatment, pancreatic is able enhance up around 20%. However, resection always associated a high risk complications and regarded as one most complex fields in abdominal surgery. This review gives summary on surgical treatment PDAC based current literature special focus techniques.

Язык: Английский

---

Therapeutic Approaches in Pancreatic Cancer: Recent Updates

Biomedicines, Год журнала: 2023, Номер 11(6), С. 1611 - 1611

Опубликована: Июнь 1, 2023

Cancer is a significant challenge for effective treatment due to its complex mechanism, different progressing stages, and lack of adequate procedures screening identification. Pancreatic cancer typically identified in advanced progression phase with low survival ~5 years. Among cancers, pancreatic also considered high mortality-causing casualty over other accidental or disease-based mortality, it ranked seventh among all mortality-associated cancers globally. Henceforth, developing diagnostic early detection, understanding cancer-linked mechanisms, various therapeutic strategies are crucial. This review describes the recent development progression, approaches, including molecular techniques biomedicines effectively treating cancer.

Язык: Английский

---

Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy

Cancer Letters, Год журнала: 2023, Номер 576, С. 216421 - 216421

Опубликована: Сен. 30, 2023

Язык: Английский

---